Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed

Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
190 Clinical Updates found
The Linear Accelerator (above), collects images to input into MSK's innovative 3D motion management platform.
MSK’s Motion Management Platform for Radiotherapy Reduces Late Urinary Toxicity in Prostate Cancer

An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared to a commercial image-guidance system, according to study results presented October 2 at the ASTRO 2023 Annual Meeting in San Diego.
The electronic nose (e-nose) is a promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK).
The E-Nose Knows: Can “Breathprint” Analysis Improve Accuracy in Lung Cancer Diagnosis?

There is a clear and unmet need for less invasive and more accurate methods for diagnosing lung cancer. A promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK) is the electronic nose (e-nose), which evaluates volatile organic compounds (VOCs) in exhaled breath. The e-nose platform detects a lung cancer-associated “breathprint” in breath from individuals with lung cancer.
Leave it in the Past: Primary Treatment Should Not Preclude Secondary Surgery in Ovarian Cancer
Leave it in the Past: Primary Treatment Should Not Preclude Secondary Surgery in Ovarian Cancer

Patients with high-grade epithelial ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking surgery (PDS), according to a retrospective study by Memorial Sloan Kettering Cancer Center (MSK) Team Ovary.
MSK researchers presented advances in new treatment approaches for several cancer indications at the 2023 ASCO annual meeting.
MSK Research Roundup at ASCO 2023: Advances in Glioma, Rectal Cancer, Lung Cancer, Biliary Tract Cancer, and More

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small cell lung cancer, biliary tract cancer, and more were as follows:
Case Study: MSK’s Approach to Complex Pediatric Surgical Oncology
Case Study: MSK’s Approach to Complex Pediatric Surgical Oncology

The American College of Surgeons recently designated Memorial Sloan Kettering Cancer Center (MSK) the first-ever Children’s Surgery Verification (CSV) Quality Improvement Program Level I Specialty Children’s Surgery Center in Oncology. The distinction recognizes MSK as a highly specialized hospital providing exceptional surgical care that matches children’s needs with optimal pediatric resources.
The Enid A. Haupt Chair in Surgery, Michael D’Angelica, MD, FACS, and Ryan Ellis, MD, MS, Chief Surgery Fellow co-authored a study that supports using piperacillin-tazobactam as a standard of care for patients undergoing open pancreatoduodenectomy.
Broad-Spectrum Antibiotic Significantly Reduces Surgical Site Infections After the Whipple Procedure

The broad-spectrum antibiotic piperacillin-tazobactam used as perioperative prophylaxis significantly reduced surgical site infection (SSI) in patients undergoing open pancreatoduodenectomy (PD, or the Whipple procedure) compared with the standard-of-care cefoxitin, according to results from the first-ever registry-linked surgical clinical trial conducted in North America. The findings, published in JAMA on April 20, support using piperacillin-tazobactam as a standard of care for this patient population.
Laboratory equipment for researchers
MSK Research Roundup at AACR 2023: Exciting Advances in Clinical, Translational, and Foundational Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest clinical, translational, and foundational cancer research at ...
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment

Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging c...
Medical Oncologist Mrinal Gounder, MD
Nirogacestat Improves Outcomes for Patients With Desmoid Tumors

Update: On November 27, 2023, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be...
physician-scientist Sarat Chandarlapaty, MD, PhD and colleague working in their MSK laboratory.
A Decade of MSK Research Laid Groundwork for Recent Approval of a Targeted Therapy for Metastatic Breast Cancer

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.